Connect with us

Hi, what are you looking for?

Markets

What To Expect From CME Group Stock?

CME Group’s stock (NYSE: CME) has gained 8% YTD, as compared to the 9% rise in the S&P500 over the same period. Further, at its current price of $182 per share, it is trading 12% below its fair value of $208 – Trefis’ estimate for CME Group’s valuation. The company outperformed the consensus estimates in the first quarter of 2023, with total revenues increasing by 7% y-o-y to $1.4 billion. It was primarily driven by a 5% improvement in clearing & transaction fees, followed by a 9% increase in market data & information services revenues. Notably, the clearing & transaction fees benefited from a 4% growth in the aggregate average daily volume, mainly driven by a 26% jump in the interest rates contracts. On the cost front, total expenses rose by 8% y-o-y, reducing the operating margin from 63.8% to 63.4%. However, the non-operating income increased from $57.2 million to $243.2 million, more than making up for higher expenses. Overall, the net income grew 24% y-o-y to $883.8 million.

The company’s top line grew 7% y-o-y to $5 billion in FY 2022, driven by a 10% improvement in clearing & transaction fees and a 6% increase in market data & information services revenues. The growth in clearing & transaction fees was driven by higher trading activity – aggregate ADV was up 19% y-o-y. That said, the non-operating income decreased from $728.4 million to $474.4 million in the year. It resulted in a net income of $2.7 billion – up 2% y-o-y.

Moving forward, we expect the higher trading volumes to continue in the subsequent quarters. Altogether, CME Group revenues are estimated to touch $5.36 billion in FY2023. Additionally, CME’s adjusted net income margin is likely to be around $3.1 billion in the year. This coupled with an annual EPS of $8.55 and a P/E multiple of just above 24x will lead to a valuation of $208.

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

This article was written by Follow I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared...